The treatment involves injecting a specially-formulated chemical - known as ATX-101 - into the skin to kill off fat cells under the chin, known as 'submental fat', or double chins.
While injectable drugs such as Botox and dermal fillers can plump and smooth the face, tackling a double chin usually means more radical surgery.
The new drug is a version of deoxycholic acid, a molecule that occurs naturally in the body to help destroy fat, 'The Telegraph' reported.
It reduces submental fat by irreversibly disrupting fat cell membranes and causing destruction of fat cells.
Manufacturers Kythera Biopharmaceuticals Inc in the US said more than 90 per cent of those who tried the drug maintained a meaningful reduction of fat after two years.
Currently, those who are unhappy with a double chin can try liposuction or neck and face lifts to get rid of the excess.
But the invasive treatments are not suitable for everyone, and require anaesthesia, an operating room and qualified staff, increasing risks and costs.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
